Literature DB >> 34168461

Progesterone Receptor Together with PKCα Expression as Prognostic Factors for Astrocytomas Malignancy.

Denisse Arcos-Montoya1, Talia Wegman-Ostrosky2,3, Sonia Mejía-Pérez4, Marisol De la Fuente-Granada1, Ignacio Camacho-Arroyo5, Alejandro García-Carrancá6, Marco A Velasco-Velázquez7, Joaquín Manjarrez-Marmolejo8, Aliesha González-Arenas1.   

Abstract

INTRODUCTION: Astrocytomas are the most common and aggressive primary brain tumors, and they are classified according to the degree of malignancy on a scale of I to IV, in which grade I is the least malignant and grade IV the highest. Many factors are related to astrocytomas progression as progesterone receptor (PR), whose transcriptional activity could be regulated by phosphorylation by protein kinase C alpha (PKCα) at the residue Ser400. Our aim was to investigate if PR phosphorylation together with PKCα expression could be used as a prognostic factor for astrocytomas malignancy.
METHODS: By immunofluorescence, we detected the content of PKCα, PR and its phosphorylation at Ser400 in 46 biopsies from Mexican patients with different astrocytoma malignancy grades; by bioinformatic tools using TCGA data, we evaluated the expression of PR and PKCα mRNA according to astrocytoma malignancy grades. For all statistical analyses, significance was p<0.05.
RESULTS: We detected a positive correlation between the tumor grade and the content of PKCα, PR and its phosphorylation at Ser400, as well as the intracellular colocalization of these proteins. Interestingly, using an in silico assay, we found that the PR and PKCα expression at mRNA level has an inverse ratio with astrocytomas tumor grade. DISCUSSION: These results indicate that PR and its phosphorylation at Ser400 site, as well as PKCα and their colocalization, could be considered as possible malignancy biomarkers for astrocytomas grades I-IV.
© 2021 Arcos-Montoya et al.

Entities:  

Keywords:  astrocytoma; biomarker; glioblastoma; progesterone receptor; protein kinase C alpha

Year:  2021        PMID: 34168461      PMCID: PMC8217595          DOI: 10.2147/OTT.S280314

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


  40 in total

Review 1.  Regulation of gene expression by progesterone in cancer cells: effects on cyclin D1, EGFR and VEGF.

Authors:  Olivia Tania Hernández-Hernández; Ignacio Camacho-Arroyo
Journal:  Mini Rev Med Chem       Date:  2013-04-01       Impact factor: 3.862

Review 2.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors:  Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-10-01       Impact factor: 12.300

3.  Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors.

Authors:  H Khalid; S Shibata; M Kishikawa; A Yasunaga; M Iseki; T Hiura
Journal:  Cancer       Date:  1997-12-01       Impact factor: 6.860

4.  PKCα and PKCδ activation regulates transcriptional activity and degradation of progesterone receptor in human astrocytoma cells.

Authors:  Aliesha González-Arenas; Miguel Ángel Peña-Ortiz; Valeria Hansberg-Pastor; Brenda Marquina-Sánchez; Noemi Baranda-Ávila; Karen Nava-Castro; Alejandro Cabrera-Wrooman; Jesús González-Jorge; Ignacio Camacho-Arroyo
Journal:  Endocrinology       Date:  2014-12-16       Impact factor: 4.736

5.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

6.  Progesterone receptor isoforms expression pattern in human astrocytomas.

Authors:  G González-Agüero; R Ondarza; A Gamboa-Domínguez; M A Cerbón; I Camacho-Arroyo
Journal:  Brain Res Bull       Date:  2001-09-01       Impact factor: 4.077

7.  Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway.

Authors:  Aliesha González-Arenas; Paulina Valadez-Cosmes; Carolina Jiménez-Arellano; Mónica López-Sánchez; Ignacio Camacho-Arroyo
Journal:  J Steroid Biochem Mol Biol       Date:  2014-09-12       Impact factor: 4.292

8.  A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.

Authors:  Shai Rosenberg; Iva Simeonova; Franck Bielle; Maite Verreault; Bertille Bance; Isabelle Le Roux; Mailys Daniau; Arun Nadaradjane; Vincent Gleize; Sophie Paris; Yannick Marie; Marine Giry; Marc Polivka; Dominique Figarella-Branger; Marie-Hélène Aubriot-Lorton; Chiara Villa; Alexandre Vasiljevic; Emmanuèle Lechapt-Zalcman; Michel Kalamarides; Ariane Sharif; Karima Mokhtari; Stefano Maria Pagnotta; Antonio Iavarone; Anna Lasorella; Emmanuelle Huillard; Marc Sanson
Journal:  Nat Commun       Date:  2018-06-18       Impact factor: 14.919

9.  Mifepristone Overcomes Tumor Resistance to Temozolomide Associated with DNA Damage Repair and Apoptosis in an Orthotopic Model of Glioblastoma.

Authors:  Monserrat Llaguno-Munive; Mario Romero-Piña; Janeth Serrano-Bello; Luis A Medina; Norma Uribe-Uribe; Ana Maria Salazar; Mauricio Rodríguez-Dorantes; Patricia Garcia-Lopez
Journal:  Cancers (Basel)       Date:  2018-12-22       Impact factor: 6.639

Review 10.  Immunological Evasion in Glioblastoma.

Authors:  Roxana Magaña-Maldonado; Elda Georgina Chávez-Cortez; Nora Karen Olascoaga-Arellano; Mariana López-Mejía; Fernando Manuel Maldonado-Leal; Julio Sotelo; Benjamín Pineda
Journal:  Biomed Res Int       Date:  2016-05-15       Impact factor: 3.411

View more
  3 in total

1.  Effects of progesterone on T-type-Ca2+-channel expression in Purkinje cells.

Authors:  Annika Eickhoff; Jonas Tjaden; Sarah Stahlke; Matthias Vorgerd; Verena Theis; Veronika Matschke; Carsten Theiss
Journal:  Neural Regen Res       Date:  2022-11       Impact factor: 6.058

Review 2.  Rapid Actions of the Nuclear Progesterone Receptor through cSrc in Cancer.

Authors:  Claudia Bello-Alvarez; Carmen J Zamora-Sánchez; Ignacio Camacho-Arroyo
Journal:  Cells       Date:  2022-06-18       Impact factor: 7.666

3.  ENPP2 Methylation in Health and Cancer.

Authors:  Maria Panagopoulou; Dionysios Fanidis; Vassilis Aidinis; Ekaterini Chatzaki
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.